Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

The addition of etoposide to CHOP is associated with improved outcome in ALK+ adult anaplastic large cell lymphoma : A Nordic Lymphoma Group study

Cederleuf, Henrik LU ; Bjerregård Pedersen, Martin ; Jerkeman, Mats LU ; Relander, Thomas LU ; d'Amore, Francesco and Ellin, Fredrik LU (2017) In British Journal of Haematology 178(5). p.739-746
Abstract

Anaplastic large cell lymphomas (ALCLs) are rare CD30+ peripheral T-cell lymphomas (PTCLs) classified according to the expression of the anaplastic lymphoma kinase (ALK+) protein or not (ALK-). We have analysed the outcome and risk factors for survival in a population-based bi-national cohort of patients with systemic ALK+ ALCL. A total of 122 adult (≥18 years) patients diagnosed with ALK+ ALCL between 2000 and 2010 were identified from the Danish and Swedish lymphoma registries, representing 0·4% of all lymphomas. The median age of the cohort was 40 years (range 18-85). The 5-year overall survival and progression-free survival (PFS) was 78% and 64%, respectively. Age was strongly associated with outcome, and only bone marrow (BM)... (More)

Anaplastic large cell lymphomas (ALCLs) are rare CD30+ peripheral T-cell lymphomas (PTCLs) classified according to the expression of the anaplastic lymphoma kinase (ALK+) protein or not (ALK-). We have analysed the outcome and risk factors for survival in a population-based bi-national cohort of patients with systemic ALK+ ALCL. A total of 122 adult (≥18 years) patients diagnosed with ALK+ ALCL between 2000 and 2010 were identified from the Danish and Swedish lymphoma registries, representing 0·4% of all lymphomas. The median age of the cohort was 40 years (range 18-85). The 5-year overall survival and progression-free survival (PFS) was 78% and 64%, respectively. Age was strongly associated with outcome, and only bone marrow (BM) involvement was independently associated with poorer PFS in multivariate analysis (Hazard Ratio [HR] = 8·57, P < 0·001). Age stratification of the patients demonstrated an association between treatment with CHOEP (cyclophosphamide, doxorubicin, vincristine, etoposide, prednisolone) and improved overall survival for patients aged 41-65 years, even when adjusted for risk factors (HR = 0·38, P = 0·047). Our results suggest that the addition of etoposide to CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) in the treatment for ALK+ ALCL seems reasonable in this age group.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Anaplastic large cell lymphoma, Bone marrow involvement, Etoposide, Peripheral T-cell lymphoma, Population-based
in
British Journal of Haematology
volume
178
issue
5
pages
739 - 746
publisher
Wiley-Blackwell
external identifiers
  • pmid:28485010
  • wos:000407904100011
  • scopus:85019077258
ISSN
0007-1048
DOI
10.1111/bjh.14740
language
English
LU publication?
yes
id
5c642817-c155-46b6-a54f-2ea367b37984
date added to LUP
2017-06-01 13:09:18
date last changed
2024-05-26 16:44:31
@article{5c642817-c155-46b6-a54f-2ea367b37984,
  abstract     = {{<p>Anaplastic large cell lymphomas (ALCLs) are rare CD30+ peripheral T-cell lymphomas (PTCLs) classified according to the expression of the anaplastic lymphoma kinase (ALK+) protein or not (ALK-). We have analysed the outcome and risk factors for survival in a population-based bi-national cohort of patients with systemic ALK+ ALCL. A total of 122 adult (≥18 years) patients diagnosed with ALK+ ALCL between 2000 and 2010 were identified from the Danish and Swedish lymphoma registries, representing 0·4% of all lymphomas. The median age of the cohort was 40 years (range 18-85). The 5-year overall survival and progression-free survival (PFS) was 78% and 64%, respectively. Age was strongly associated with outcome, and only bone marrow (BM) involvement was independently associated with poorer PFS in multivariate analysis (Hazard Ratio [HR] = 8·57, P &lt; 0·001). Age stratification of the patients demonstrated an association between treatment with CHOEP (cyclophosphamide, doxorubicin, vincristine, etoposide, prednisolone) and improved overall survival for patients aged 41-65 years, even when adjusted for risk factors (HR = 0·38, P = 0·047). Our results suggest that the addition of etoposide to CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) in the treatment for ALK+ ALCL seems reasonable in this age group.</p>}},
  author       = {{Cederleuf, Henrik and Bjerregård Pedersen, Martin and Jerkeman, Mats and Relander, Thomas and d'Amore, Francesco and Ellin, Fredrik}},
  issn         = {{0007-1048}},
  keywords     = {{Anaplastic large cell lymphoma; Bone marrow involvement; Etoposide; Peripheral T-cell lymphoma; Population-based}},
  language     = {{eng}},
  number       = {{5}},
  pages        = {{739--746}},
  publisher    = {{Wiley-Blackwell}},
  series       = {{British Journal of Haematology}},
  title        = {{The addition of etoposide to CHOP is associated with improved outcome in ALK+ adult anaplastic large cell lymphoma : A Nordic Lymphoma Group study}},
  url          = {{http://dx.doi.org/10.1111/bjh.14740}},
  doi          = {{10.1111/bjh.14740}},
  volume       = {{178}},
  year         = {{2017}},
}